Glaukos Q2 Sales Surge 50%, Guidance Raised to $700M on iDose TR and Epioxa Momentum
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (3.0× avg).
Summary
Glaukos reported Q2 2026 net sales of $185.6 million, up 50% year-over-year, and raised full-year guidance to $680-$700 million. The beat was fueled by accelerating adoption of iDose TR and the initial launch of Epioxa.
Key Events · Earnings and Guidance · GKOS
-
Record Q2 Revenue, +50% YoY
Net sales reached $185.6 million, with U.S. glaucoma up 64% to $118.5 million. iDose TR contributed ~$74 million and Epioxa added ~$11 million in its first full quarter.
-
Full-Year Guidance Raised to $680M-$700M
Management lifted the 2026 revenue outlook from $620M-$635M, reflecting strong momentum in iDose TR adoption and Epioxa launch progress.
-
Gross Margin Expansion
Non-GAAP gross margin improved to ~85% from ~83% a year ago, driven by favorable product mix and operating leverage.
-
Strong Balance Sheet
Cash and short-term investments totaled $289.3 million with no debt, providing ample runway for continued R&D and commercial investments.
Analysis · GKOS · Industrial Applications And Services
Glaukos delivered a standout quarter with net sales jumping 50% to $185.6 million, driven by 64% growth in U.S. glaucoma sales. The company raised its full-year revenue outlook by $65 million at the midpoint, signaling confidence in the commercial launches of iDose TR and Epioxa. Gross margins expanded to 85% on a non-GAAP basis, and the balance sheet remains debt-free with $289 million in cash. This earnings beat and guidance raise materially improve the growth trajectory and de-risk the path to profitability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GKOS was trading at $178.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $166.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.